

SHORT REPORT

Open Access



Evolution of changes in cognitive function after the initiation of antiretroviral therapy

Borja Mora-Peris^{1,2*}, Elizabeth Stevens³, Francesca Ferretti⁴, Jonathan Underwood¹, Stephen Taylor^{3,5} and Alan Winston^{1,2}

Abstract

Background: Cognitive function is reported to improve after the initiation of combination antiretroviral therapy (cART). Data on the evolution of such changes are limited. We assessed the dynamics of changes in cognitive parameters, in HIV-positive subjects initiating cART.

Methods: Cognitive function in seven domains was evaluated for HIV-infected patients without clinically significant cognitive impairment prior to the initiation of cART, and 24 and 48 weeks after. Cognitive scores were transformed using standardised z-scores according to the pooled baseline standard deviation. Global, speed, and accuracy composite z-scores were calculated with changes calculated using a paired t test.

Results: In 14 subjects, change in global cognitive z-scores from baseline was by 0.08 at week 24 ($p = 0.59$) and 0.15 at week 48 ($p = 0.43$). Change in composite speed and accuracy z-scores from baseline at weeks 24/48 were 0.07/0.05 ($p = 0.45/0.82$) and 0.13/0.23 ($p = 0.47/0.45$), respectively. In two of the cognitive domains assessing speed (learning and monitoring time), a continued improvement from baseline to weeks 24 and 48 was observed (changes of 0.06–0.08 and 0.10–0.19, respectively), whereas in two domains (detection and identification) an initial improvement at week 24 (changes of -0.10 and 0.04 from baseline, respectively) was followed by a deterioration in score at week 48 (changes of -0.12 and -0.08 from baseline, respectively). None of these changes were statistically significant.

Conclusions: A trend for improvement in cognitive function was observed in naïve HIV-positive patients starting cART. The dynamics of this improvement differed both between cognitive domains and the time-points assessed.

Keywords: Cognitive function, cART, Naïve, HIV, Nevirapine

Background

Cognitive impairment is a frequently reported complication in otherwise effectively treated HIV-positive individuals [1, 2]. The presence of HIV-associated cognitive impairment has been associated with reduced quality of life and higher mortality [3, 4].

In general, improvements in cognitive function have been reported in patients initiating antiretroviral therapy [5–7]. Data describing the dynamics of changes in

cognitive function after the initiation of cART are sparse [8, 9]. An understanding of the dynamics of these changes is crucial to assist in the design of future research programmes assessing cognitive function within longitudinal cohorts and to assist in diagnostic algorithms for cognitive impairment in treated HIV-disease.

The aim of this study was to assess changes in cognitive parameters and the dynamics of these changes within individual cognitive domains in people living with HIV (PLWH) commencing antiretroviral therapy.

*Correspondence: b.mora-peris@imperial.ac.uk

¹ Clinical Trials, Faculty of Medicine, Winston Churchill Wing, St. Mary's Hospital, Imperial College, Praed Street, London W2 1NY, UK
Full list of author information is available at the end of the article

Methods

Study design and procedures

This analysis was undertaken as part of an open-labelled, randomised, prospective clinical trial conducted at Imperial College Healthcare NHS Trust (St Mary's Hospital, London, UK) and the Heart of England NHS Foundation Trust (Birmingham, UK) between February 2008 and October 2012.

Within the study protocol, subjects were randomised on a 1:1 basis to emtricitabine (200 mg once daily) + tenofovir disoproxil fumarate (245 mg once daily) plus either atazanavir (300 mg once daily) + ritonavir (100 mg once daily) or nevirapine 400 mg (once daily).

Subject selection

ART-naïve, HIV-positive patients aged over 18, with no clinically overt cognitive impairment or abnormalities on screening laboratory testing were eligible to participate. In line with national prescribing guidelines for the use of nevirapine as an antiretroviral agent, CD4+ lymphocyte count <400 cells/ μ L and <250 cells/ μ L were required for males and females, respectively. Exclusion criteria included current history of major psychiatric disorders, significant co-morbidities, use of concomitant medication with potential drug–drug interactions, or evidence of HIV-1 genotypic resistance mutations.

This study was registered in the European Clinical Trials Database (EudraCT number 2007-002405-47) and national human ethics committee approval was granted prior to recruitment. All patients gave informed consent before screening.

Cognitive testing

A computerised cognitive test battery (CogState™) [10, 11] was performed at baseline, weeks 24 and 48. This battery comprised of seven tasks and required approximately 10–15 min to complete. The tasks were in the form of card games and specifically assessed the following domains: detection, identification, monitoring and matched learning (all assessed via speed of test); associate learning, one card learning and working memory (assessed via accuracy of test). All study participants completed one full practise test prior to study examination to optimize performance at baseline.

Statistical methods

We initially aimed to recruit 40. Given only 14 subjects completed our study, this analysis is descriptive with no formal comparisons across treatment arms.

All statistical calculations were performed using SPSS (version 22.0; SPSS Inc., Chicago, IL, USA) and analysis was conducted according to CogState™ recommendations. Reaction times were \log_{10} -transformed because of

a positive skew of the distribution, and accuracy measures were transformed using arcsine-root transformation. For each subject, results were standardized as z-scores according to the pooled baseline standard deviation (SD) for each domain.

Composite z-scores were calculated overall (global) and for the speed and accuracy domains based on the average of standardized z-scores. Changes from baseline scores to weeks 24 and 48 were calculated for each individual and composite domain. For the calculation of composite scores and changes, z-scores involving speed domains were multiplied by -1 . This transformation allowed for all parameters a positive change to represent an improvement in function whereas a negative change from baseline represented deterioration in function. Statistical significance of changes in scores from baseline to weeks 24 and 48 was assessed for every parameter accordingly using a paired t test.

Only validated cognitive results were incorporated into the analysis.

Results

Patient characteristics

24 subjects were screened, 20 were enrolled and 14 completed all study procedures. Among those six who did not complete study procedures, four dropped out and two lacked complete cognitive data. Patient characteristics are summarised in Table 1. Plasma HIV RNA was <50 copies/mL at weeks 36 and 48 (Table 1) in all subjects.

Cognitive function changes over 48 weeks

Overall, there were improvements in cognitive function over the study period but these changes were not statistically significant. For instance, global composite changes in z-scores (SD) increased from 0.08 (0.54) at week 24 ($p = 0.59$) to 0.15 (0.60) at week 48 ($p = 0.43$) (Table 2). Likewise, the changes from baseline in composite accuracy speed z-scores (SD) increased from 0.13 (0.63) at week 24 to 0.23 (0.93) at week 48. Such improvements in z-scores were also observed in the composite speed z-scores: 0.07 (0.37) at week 24 and remained stable by 0.05 (0.67) at week 48.

All three accuracy domains (associate learning, one card learning and working memory) showed an improvement from baseline to week 24 (z-score changes of 0.01, 0.17 and 0.41, respectively). At week 48, such improvements were sustained for one card learning and working memory (z-score changes of 0.11 and 0.34 from baseline, respectively) and increased for associate learning (z-score change of 0.19 from baseline).

Speed domains such as matched learning and monitoring time showed a continued improvement from baseline

Table 1 Patient demographics and clinical characteristics throughout the study

Parameter ^a	(n=14)
Age (years; range)	37.4 (23–48)
Male, n (%)	14 (100 %)
Ethnicity (%)	
White	9 (64.3 %)
Black	3 (21.4 %)
Asian	2 (14.3 %)
Baseline CD4+ count (cells/ μ L)	280 (129)
Baseline HIV RNA (log copies/ μ L)	4.42 (0.58)
HIV-1 clade B, n (%)	10 (71.4 %)
Patients with HIV RNA <50 copies/ μ L, n (%)	
Week 24	11 (78.6 %)
Week 36	14 (100 %)
Week 48	14 (100 %)

^a Mean (SD) unless otherwise stated. No statistically significant differences ($p > 0.1$) for any parameters between study arms

to week 24 and then to week 48 (changes of 0.06 to 0.08 and 0.10 to 0.19, respectively), whereas others such as detection and identification showed an initial improvement at week 24 (changes of 0.10 and 0.04 from baseline, respectively) followed by a small decline at week 48 (changes of -0.12 and -0.08 from baseline, respectively) (Table 2).

Discussion

We assessed changes in cognitive parameters in HIV-positive subjects at 24 and 48 weeks after commencing cART for the first time.

We observed general trends suggesting an initial improvement in composite speed and accuracy cognitive domains at week 24, which continued to week 48 after starting cART. However, none of these trends were of statistical significance, which may be due to the small number of subjects studied.

Previous studies have reported overall neuropsychological function improvement to peak around 24–36 weeks after cART initiation with these improvements prolonged up to week 48 [6]. Similarly, in the ALTAIR study speed and accuracy domains improved over the first year after cART initiation with no individual domain showing deterioration from baseline at week 48 [7]. However, in the long term follow up of this study a decline in global cognitive function score was observed over 144 weeks and the authors hypothesised this could be related to antiretroviral toxicities [12]. In our study, domains critically affected in HIV-associated cognitive impairment such as detection and identification times [13] deteriorated slightly at week 48 after an

Table 2 Changes in Z-score neurocognitive testing parameters at weeks 24 and 48 from baseline

Cognitive domain	Overall			
	n	Z-score change	SD of change	p value
Detection ^a				
W24	14	0.10	0.68	0.59
W48	12	-0.12	0.79	0.61
Identification ^a				
W24	14	0.04	0.75	0.84
W48	11	-0.08	0.99	0.78
Matched learning ^a				
W24	14	0.06	0.71	0.76
W48	11	0.08	0.99	0.78
Monitoring time ^a				
W24	14	0.10	0.64	0.55
W48	11	0.19	0.78	0.43
Associate learning ^b				
W24	13	0.01	0.08	0.65
W48	10	0.19	0.64	0.36
One card learning ^b				
W24	14	0.17	1.27	0.62
W48	12	0.11	1.46	0.78
Working memory ^b				
W24	14	0.41	1.00	0.14
W48	11	0.34	1.30	0.41
Composite speed ^a				
W24	14	0.07	0.37	0.45
W48	11	0.05	0.67	0.82
Composite accuracy ^b				
W24	13	0.13	0.63	0.47
W48	10	0.23	0.93	0.45
Global composite ^c				
W24	13	0.08	0.54	0.59
W48	10	0.15	0.60	0.43

All change estimates are based on pooled-standard-deviation standardized z-score changes

N number of subjects, SD standard deviation of the change, CI confidence interval. Shaded areas, z-score changes

^a Used to determine speed (sp); a positive change in z-score represents an improved response

^b Used to determine accuracy (acc) of response; a positive change in z-score represents an improved response

^c A positive change in z-score represents an improved response. Global composite = composite accuracy + speed

initial improvement at week 24 (Table 2). This highlights that different dynamics of change are observed in different cognitive domains including potential fluctuations over time suggesting that different domains should be explored independently as well as a part of global cognitive assessments. Some limitations to consider while interpreting these data are the likelihood of a learning

effect despite a practice neurocognitive test at screening and the open-label nature of the study. Additionally, the lack of clinically significant cognitive impairment in the study population may have reduced the power to detect significant improvements. We recruited subjects without overt cognitive impairment based on clinical judgement. Given we do not have an appropriate control dataset we are unable to classify subjects into cognitively impaired and non-impaired based on the cognitive testing results in our study, which would be of interest after the initiation of cART [8].

We had initially planned to undertake a comparative study of two different antiretroviral treatment regimens. However, recruitment was challenging. We believe the use of nevirapine was one of the factors underlying these recruitment difficulties. Firstly, nevirapine was not recommended as preferred first line treatment for naïve patients in the UK by the time the study commenced in 2008 [14]. Secondly, only patients with low CD4 counts (<400 cells/ μ L and <250 cells/ μ L for males and females, respectively) were eligible to enter this study due to the reported increased risk of toxicity for patients with higher CD4 counts commencing nevirapine-containing cART regimens [14]. This limited the eligible population for our study. The HIV-therapeutic field continues to be a rapidly changing arena. Recent guidelines changes include recommending treatment for all PLWH, irrespective of CD4+ lymphocyte count, in view of the results from the INSIGHT-START study [15]. Therefore studies stipulating CD4+ count criteria at entry are no longer feasible or ethical. Recent treatment guidelines are swaying towards commencing therapy with an integrase-inhibitor containing regimen [16, 17]. Such changes make recruitment to studies using regimens containing non-nucleoside reverse transcriptase inhibitors such as efavirenz, which have been standard of care for almost a decade, challenging.

In summary, a general trend of improvement in cognitive function parameters was observed in naïve HIV-positive participants initiating antiretroviral therapy with the dynamics of these changes differing between cognitive parameters over 48 weeks of follow-up.

Authors' contributions

AW and ST conceived the design of the study. BMP drafted this manuscript and performed the analysis for this report. All authors contributed to the writing of the final manuscript. All authors read and approved the final manuscript.

Author details

¹ Clinical Trials, Faculty of Medicine, Winston Churchill Wing, St. Mary's Hospital, Imperial College, Praed Street, London W2 1NY, UK. ² Department of HIV and Genitourinary Medicine, Imperial College Healthcare NHS Trust St Mary's Hospital, London, UK. ³ Birmingham Heartlands HIV Service, Heart of England NHS Foundation Trust, Birmingham, UK. ⁴ Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy. ⁵ Division of Immunity and Infection, University of Birmingham, Birmingham, UK.

Acknowledgements

We are grateful to the NIHR Biomedical Facility at Imperial College London for infrastructure support. We would like to thank all the study participants, the staff at the Department of Clinical and Molecular Pharmacology of the University of Liverpool, the nursing and pharmacy staff and the Clinical Trials Centre, Imperial College London (St Mary's Campus), UK (Ken Legg, Scott Mullaney, Kristin Kuldaneck and Nadia Naous). The nursing, pharmacy and occupational therapy team of the Birmingham Heartlands HIV Service and the staff at the MIDRU research facility, Birmingham Heartlands Hospital, UK (Gerry Gilleran and Cathy Stretton).

Funding

This study was funded by an Investigator Initiated Grant from Boehringer Ingelheim (UK) to Alan Winston at Imperial College London.

Transparency declarations

AW and ST have received honoraria or research grants from or been a consultant or investigator in clinical trials sponsored by Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen-Cilag, Roche, Pfizer and ViiV Healthcare. All other authors: none to declare.

Competing interests

The authors declare that they have no competing interests.

Received: 18 December 2015 Accepted: 7 April 2016

Published online: 14 April 2016

References

- Report of a Working Group of the American Academy of Neurology AIDS Task Force. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. *Neurology*. 1991;41:778–85.
- Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, et al. HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990–1998. *Neurology*. 2001;56:257–60.
- Lescure F-X, Omland LH, Engsig FN, Roed C, Gerstoft J, Pialoux G, et al. Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. *Clin Infect Dis*. 2011;52:235–43.
- Hinkin CH, Castellon SA, Durvasula RS, Hardy DJ, Lam MN, Mason KI, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. *Neurology*. 2002;59:1944–50.
- Al-Khindi T, Zakzanis KK, van Gorp WG. Does antiretroviral therapy improve HIV-associated cognitive impairment? A quantitative review of the literature. *J Int Neuropsychol Soc*. 2011;17:1–14.
- Cysique LA, Vaida F, Letendre S, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. *Neurology*. 2009;73:342–8.
- Winston A, Puls R, Kerr SJ, et al. Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study. *HIV Med*. 2012;13:245–51.
- Nightingale S, Winston a, Letendre S, et al. Controversies in HIV-associated neurocognitive disorders. *Lancet Neurol*. 2014;13(11):1139–51.
- Chan P, Brew BJ. HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment. *Curr HIV/AIDS Rep*. 2014;11(3):317–24.
- Lezac M. *Neuropsychological Assessment*. 3rd ed ed. New York: Oxford University Press; 1995.
- Cysique LA, Maruff P, Darby D, Brew BJ. The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. *Arch Clin Neuropsychol*. 2006;21:185–94.
- Winston A, Puls R, Kerr SJ, Duncombe C, Li P, Gill JM, Ramautarsing R, Taylor-Robinson SD, Emery S, Cooper DA. ALTAIR Study Group. Differences in the direction of change of cerebral function parameters are evident over 3 years in HIV-infected individuals electively commencing initial cART. *PLoS ONE*. 2015;10(2):e0118608.

13. Hardy DJ, Hinkin CH. Reaction time performance in adults with HIV/AIDS. *J Clin Exp Neuropsychol*. 2002;24(7):912–29.
14. Gazzard BG, Anderson J, Babiker A, Boffito M, Brook G, Brough G, Churchill D, Cromarty B, Das S, Fisher M, Freedman A, Geretti AM, Johnson M, Khoo S, Leen C, Nair D, Peters B, Phillips A, Pillay D, Pozniak A, Walsh J, Wilkins E, Williams I, Williams M, Youle M. BHIVA treatment guidelines writing group. British HIV association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. *HIV Med*. 2008;9(8):563–608.
15. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. Initiation of antiretroviral therapy in early asymptomatic hiv infection. *N Engl J Med*. 2015;373(9):795–807.
16. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>. Accessed 14 Oct 2015.
17. Churchill D, Waters L, Ahmed N, Angus B, Boffito M, Bower M, Dunn D, Edwards S, Emerson C, Fidler S, Fisher M, Horne R, Khoo S, Leen C, Mackie N, Marshall N, Monteiro F, Nelson M, Orkin C, Palfreeman A, Pett S, Phillips A, Post F, Pozniak A, Reeves I, Sabin C, Trevelion R, Walsh J, Wilkins E, Williams I, Winston A British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. <http://www.bhiva.org/documents/Guidelines/Treatment/2015/2015-treatment-guidelines.pdf>. Accessed 19 Oct 2015.

Submit your next manuscript to BioMed Central
and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

